Gelsomino, Francesco

Lessons to be learnt from real-world studies on immune-related adverse events with checkpoint inhibitors: a clinical perspective from pharmacovigilance

Raschi, E., Gatti, M., Gelsomino, F., Ardizzoni, A., Poluzzi, E., & De Ponti, F. (2020) · Targeted Oncology

Cancer Immunotherapy and BiomarkersPharmacovigilance and Adverse Drug Reactions

Cited by 157

Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations

Passiglia, F., Cappuzzo, F., Alabiso, O., Bettini, A. C., Bidoli, P., Chiari, R., Defferrari, C., Delmonte, A., Finocchiaro, G., Francini, G., et al. (2019) · British Journal of Cancer

Lung Cancer Treatments and MutationsCancer Immunotherapy and Biomarkers

Cited by 81